These results may be related to increased CD86 expression observed in resistant CLL cells: in a patient treated with venetoclax, the CD86 levels decreased during the treatment and then increased again a few months before the onset of clinical resistance.46 This evidence concerns the gene CD86 and B-cell chronic lymphocytic leukemia.